Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia

British Journal of Cancer

Volumn 88, Issue 5, 2003, Pages 775-781

  Kaaijk, P ^a   Kaspers, G J L ^a   Van Wering, E R ^b   Broekema, G J ^a   Loonen, A H ^a   Hahlen K ^b,c   Schmiegelow, K ^d   Janka Schaub, G E ^e   Henze, G ^f   Creutzig, U ^g   Veerman, A J P ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d Rigshospitalet   (Denmark)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Cell proliferation; Childhood leukaemia; Drug resistance

Indexed keywords

4 HYDROPEROXYIFOSFAMIDE; ACLARUBICIN; ASPARAGINASE; CYCLINE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE SODIUM PHOSPHATE; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; KI 67 ANTIGEN; MERCAPTOPURINE; MITOXANTRONE; PREDNISOLONE SODIUM PHOSPHATE; TENIPOSIDE; TIOGUANINE; VINCRISTINE;

ACCURACY; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; AGE; ANTIGEN EXPRESSION; ARTICLE; BLOOD SAMPLING; BONE MARROW; CANCER CELL; CELL CYCLE S PHASE; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SENSITIVITY; GENDER; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; LEUKOCYTE COUNT; PRIORITY JOURNAL;

ACUTE DISEASE; CELL DIVISION; CHILD; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LEUKEMIA, MYELOID; S PHASE;

EID: 0037430005     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600787     Document Type: Article

References (37)

1. Asselin BL, Kreissman S, Coppola DJ, Bernal SD, Leavitt PR, Gelber RD, Sallan SE, Cohen HJ (1999) Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 21: 6-12
2. Bai A, Kojima H, Hori M, Nara N, Komeno T, Hasegawa Y, Ninomiya H, Abe T, Nagasawa T (1999) Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells. Exp Hematol 27: 259-265
3. Braess J, Jahns-Streubel G, Schoch C, Haase D, Haferlach T, Fiegl M, Voss S, Kern W, Schleyer E, Hiddemann W (2001) Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia. Br J Haematol 113: 975-982
4. Butturini A, Santucci MA, Gale RP, Perocco P, Tura S (1990) GM-CSF incubation prior to treatment with cytarabine or doxorubicin enhances drug activity against AML cells in vitro: a model for leukemia chemotherapy. Leuk Res 14: 743-749
5. Creutzig U, Ritter J, Schellong G (1990) Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group. Blood 75: 1932-1940
6. Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F, Henze G, Jurgens H, Kabisch H, Havers W, Reiter A, Kluba U, Niggli F, Gadner H (2001) Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol 19: 2705-2713
7. Dow LW, Chang LJ, Tsiatis AA, Melvin SL, Bowman WP (1982) Relationship of pretreatment lymphoblast proliferative activity and prognosis in 97 children with acute lymphoblastic leukemia. Blood 59: 1197-1202
8. Duque RE, Andreeff M, Braylan RC, Diamond LW, Peiper SC (1993) Consensus review of the clinical utility of DNA flow cytometry in neoplastic hematopathology. Cytometry 14: 492-496
9. Eckert C, Biondi A, Seeger K, Cazzaniga G, Hartmann R, Beyermann B, Pogodda M, Proba J, Henze G (2001) Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 358: 1239-1241
10. Hongo T, Yajima S, Sakurai M, Horikoshi Y, Hanada R. (1997) In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood 89: 2959-2965
11. Ito M, Tsurusawa M, Zha Z, Kawai S, Takasaki Y, Fujimoto T (1992) Cell proliferation in childhood acute leukemia. Comparison of Ki67 and proliferating cell nuclear antigen immunocytochemical and DNA flow cytometric analysis. Cancer 69: 2176-2182
12. Jackson G, Taylor P, Smith GM, Marcus R, Smith A, Chu P, Littlewood TJ, Duncombe A, Hutchinson M, Mehta AB, Johnson SA, Carey P, MacKie MJ, Ganly PS, Turner GE, Deane M, Schey S, Brookes J, Tollerfield SM, Wilson MP (2001) A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol 112: 127-137
13. Kamikubo KH, Ogata K, An E, Dan K (2000) Low proportion of GO-phase cells during induction chemotherapy correlates with subsequent remission in acute myeloid leukemia. Int J Hematol 71: 249-255
14. Kaspers GJ, Pieters R, Van Zantwijk CH, De Laat PA, De Waal FC, van Wering ER, Veerman AJP (1991) In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br J Cancer 64: 469-474
15. Kaspers GJ, Pieters R, Van Zantwijk CH, van Wering ER, Van Der Does-Van Den Berg A, Veerman AJP (1998) Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro - vivo correlations and cross-resistance to other drugs. Blood 92: 259-266
16. Kaspers GJ, Veerman AJP, Pieters R, Broekema GJ, Huismans DR, Kazemier KM, Loonen AH, Rottier MA, Van Zantwijk CH, Hählen K et al (1994) Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methylthiazol - tetrazolium assay. Br J Cancer 70: 1047-1052
17. Kaspers GJ, Veerman AJP, Pieters R, Van Zantwijk CH, Smets LA, van Wering ER, Van Der Does-Van Den Berg A (1997) In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 90: 2723-2729
18. Kellner U, Rudolph P, Parwaresch R (2000) Human DNA-topoisomerases. Therapeutic and diagnostic implications for cancer. Onkologie 23: 424-430
19. Kersey JH (1997) Fifty years of studies of the biology and therapy of childhood leukemia. Blood 90: 4243-4251
20. Klumper E, Pieters R, Kaspers GJ, Huismans DR, Loonen AH, Rottier MM, van Wering ER, Van Der Does-Van den Berg DB, Hählen K, Creutzig U (1995a) In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia. Leukemia 9: 1864-1869
21. Klumper E, Pieters R, Veerman AJP, Huismans DR, Loonen AH, Hahlen K, Kaspers GJ, van Wering ER, Hartmann R, Henze G (1995b) In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 86: 3861-3868
22. Look AT, Melvin SL, Williams DL, Brodeur GM, Dahl GV, Kalwinsky DK, Murphy SB, Mauer AM (1982) Aneuploidy and percentage of S-phase cells determined by flow cytometry correlate with cell phenotype in childhood acute leukemia. Blood 60: 959-967
23. Montillo M, Mirto S, Petti MC, Latagliata R, Magrin S, Pinto A, Zagonel V, Mele G, Tedeschi A, Ferrara F (1998) Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol 58: 105-109
24. Nyvold C, Madsen HO, Ryder LP, Seyfarth J, Svejgaard A, Clausen N, Wesenberg F, Jonsson OG, Forestier E, Schmiegelow K (2002) Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 99: 1253-1258
25. Pui CH, Crist WM, Look AT (1990) Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood 76: 1449-1463
26. Pui CH, Evans WE (1998) Acute lymphoblastic leukemia. N Engl J Med 339: 605-615
27. Pui CH, Evans WE (1999) Genetic abnormalities and drug resistance in acute lymphoblastic leukemia. Adv Exp Med Biol 457: 383-389
28. Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D, Riehm H (1994) Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84: 3122-3133
29. Smets LA, Slater R, van Wering ER, Does-van den Berg A, Hart AA, Veerman AJ, Kamps WA (1995) DNA index and %S-phase cells determined in acute lymphoblastic leukemia of children: a report from studies ALL V, ALL VI, and ALL VII (1979-1991) of the Dutch Childhood Leukemia Study Group and The Netherlands Workgroup on Cancer Genetics and Cytogenetics. Med Pediatr Oncol 25: 437-444
30. Smets LA, Taminiau J, Hahlen K, de Waal F, Behrendt H (1983) Cell kinetic responses in childhood acute nonlymphocytic leukemia during high-dose therapy with cytosine arabinoside. Blood 61: 79-84
31. Stevens RF, Hann IM, Wheatley K, Gray RG (1998) Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol 101: 130-140
32. Tsurusawa M, Ito M, Zha Z, Kawai S, Takasaki Y, Fujimoto T (1992) Cell-cycle-associated expressions of proliferating cell nuclear antigen and Ki67 reactive antigen of bone marrow blast cells in childhood acute leukemia. Leukemia 6: 669-674
33. Van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, Does-van den Berg A, Hop WC, Riehm H, Bartram CR (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352: 1731-1738
34. Vidriales MB, Orfao A, Lopez-Berges MC, Gonzalez M, Lopez-Macedo A, Ciudad J, Lopez A, Garcia MA, Hernandez J, Borrego D, San Miguel JF (1995) Prognostic value of S-phase cells in AML patients. Br J Haematol 89: 342-348
35. Vindelov LL, Christensen IJ, Nissen NI (1983a) A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3: 323-327
36. Vindelov LL, Christensen IJ, Nissen NI (1983b) Standardization of high-resolution flow cytometric DNA analysis by the simultaneous use of chicken and trout red blood cells as internal reference standards. Cytometry 3: 328-331
37. Zwaan CM, Kaspers GJL, Pieters R, Ramakers-Van Woerden NL, den Boer ML, Wunsche R, Rottier MMA, Hahlen K, van Wering ER, Janka-Schaub GE, Creutzig U, Veerman AJP (2000) Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and with acute lymphoblastic leukemia. Blood 96: 2879-2886